Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Maculaitis MC, Liu X, Berk A, Massa A, Weiss MC, Kurosky SK, Li B, McRoy L March 6, 2022 MBCC 2022 Breast Cancer

Psychosocial well-being and healthcare resource utilization among patients with breast cancer during COVID-19

View Presentation
Poster
Engel-Nitz NM, Kurosky SK, Johnson MG, Johnson MP, Liu X March 6, 2022 MBCC 2022 Breast Cancer

Real-world adherence and persistence with palbociclib treatment among insured patients with HR+/HER2- metastatic breast cancer in the United States

View Presentation
Poster
Mahtani RL, Ivanova J, Falkenstein A, Niyazov A, Ryan JC, Kish J, Gajra A, Zimmerman Savill KM March 6, 2022 MBCC 2022 Breast Cancer

Real-world patient characteristics, treatment patterns, and clinical outcomes among talazoparib-treated patients with HER2-negative, locally advanced or metastatic breast cancer and germline BRCA mutations

View Presentation
Oral Presentation
Furlanetto J, Marmé F, Thode C, Nekljudova V, Liu Y, Martin M, Reimer T, Knudsen E, Denkert C, Bassy M, Martin L-A, Karn T, Sinn B, Filipits M, van Mackelenbergh M, Fasching PA, Müller V, Stickeler E, Schem C, Loibl S May 3, 2022 ESMO BC 2022 Breast Cancer

Ovarian Function in Young Patients Treated With Postneoadjuvant Palbociclib and Endocrine Therapy for HR-positive, HER2-negative Early Breast Cancer (BC): Explorative Analysis in Penelope-B

View Presentation
Poster
Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A May 4, 2022 ESMO BC 2022 Breast Cancer

Overall Survival With First-line Palbociclib Plus an Aromatase Inhibitor (AI) vs AI in Metastatic Breast Cancer: A Large Real-World Database Analysis

View Presentation View Abstract Plain Language Summary
Poster
Karuturi MS, Blum JL, Anderson D, Kurian S, Wilks S, Wang G, Gauthier E, Zhang Z, Wang Y, Tripathy D, Rocque G May 4, 2022 ESMO BC 2022 Breast Cancer

Palbociclib Treatment in Pre/Perimenopausal Women With Advanced/Metastatic Breast Cancer (ABC/mBC): Real-World Patient Characteristics, Treatment Patterns, and Outcomes Data From POLARIS

View Presentation View Abstract Plain Language Summary
Oral Presentation
Finn RS, Rugo HS, Dieras V, Harbeck N, Im S-A, Gelmon KA, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Slamon DJ June 4, 2022 ASCO 2022 Breast Cancer

Overall Survival (OS) With First-Line Palbociclib Plus Letrozole (PAL+LET) Versus Placebo Plus Letrozole (PBO+LET) in Women with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (ER+/HER2− ABC): Analyses From PALOMA-2

View Presentation View Abstract Plain Language Summary
Poster
Yeh C, Zhou M, Bapodra N, Rivero M, Espinal-Dominguez E, Moran M, Hershman DL, Fojo T, Bates SE June 6, 2022 ASCO 2022 Breast Cancer

A Novel Analysis of Data From the PALOMA-3 Trial Confirms the Efficacy of Palbociclib and Provides an Option for Efficacy Assessments that Could Accelerate Drug Approvals

View Presentation View Abstract Plain Language Summary
Poster
Pascual J, Martin M,   Proszek P,   Gil-Gil M,   Reay A,   Zielinski C,   Herranz J, Cutts R, Ruiz-Borrego M, Feber A, Ciruelos EM, Swift C, Munoz M, Bermejo B, Margeli M, Li Y, García-Murillas I,   Hubank M, Turner NC June 6, 2022 ASCO 2022 Breast Cancer

Baseline and Longitudinal ctDNA Biomarkers in GEICAM/2013-02 (PEARL) Trial Cohort 2 Comparing Palbociclib and Fulvestrant (PAL + FUL) versus Capecitabine (CAPE)

View Presentation
Poster
Hu X, Broughton E, Li W, Sun T, Shen K, Huang C-S, Sriuranpong V, Ngan KCR, Chia YH, Bhattacharyya H, Zhao H, Shen J, Xu B September 10, 2022 ESMO 2022 Breast Cancer

Patient-Reported Quality of Life in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole: Results From PALOMA-4

View Presentation View Abstract Plain Language Summary